Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation

Schizophrenia Research

Volumn 140, Issue 1-3, 2012, Pages 1-8

  Harvey, Philip D ^a   Heaton, Robert K ^b   Carpenter, William T ^c   Green, Michael F ^d   Gold, James M ^c   Schoenbaum, Michael ^e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UCSD MEDICAL CENTER   (United States)

^c Maryland Psychiatric Research Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Disability; Employment

Indexed keywords

NEUROLEPTIC AGENT;

COMPENSATION; DAILY LIFE ACTIVITY; DIAGNOSTIC VALUE; DISABILITY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG RESPONSE; EMPLOYABILITY; FUNCTIONAL ASSESSMENT; FUNCTIONAL DISEASE; HUMAN; MOTIVATION; NATIONAL HEALTH ORGANIZATION; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION; SOCIAL SECURITY;

ACTIVITIES OF DAILY LIVING; COGNITION DISORDERS; DISABILITY EVALUATION; DISABLED PERSONS; ELIGIBILITY DETERMINATION; EMPLOYMENT; HUMANS; INSURANCE, DISABILITY; MOTIVATION; PSYCHOTIC DISORDERS; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR; SOCIAL SECURITY; UNITED STATES; UNITED STATES SOCIAL SECURITY ADMINISTRATION; WORKERS' COMPENSATION;

EID: 84865347535     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.03.025     Document Type: Review

References (72)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1980, Washington, DC. 3rd Edition.
2. Becker D.R., Drake R.E., Bond G.R., Xie H., Dain B.J., Harrison K. Job terminations among people with severe mental illness participating in supported employment. Community Ment. Health J. 1998, 34:71-82.
3. Bowie C.R., Leung W.W., Reichenberg A., McClure M.M., Patterson T.L., Heaton R.K., et al. Predicting schizophrenia patients' real world behavior with specific neuropsychological and functional capacity measure. Biol. Psychiatry 2008, 63:505-511.
4. Bowie C.R., Depp C., McGrath J.A., Wolyniec P., Mausbach B.T., Thornquist M.H., et al. Prediction of real world functional disability in chronic mental disorders: a comparison of schizophrenia and bipolar disorder. Am. J. Psychiatry 2010, 167:1116-1124.
5. Breier A., Schreiber J.L., Dyer J., Pickar D. National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch. Gen. Psychiatry 1991, 48:239-246.
6. Bryson G., Bell M.D. Initial and final work performance in schizophrenia: cognitive and symptom predictors. J. Nerv. Ment. Dis. 2003, 19:87-92.
7. Buckley P.F., Harvey P.D., Bowie C.R., Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr. Res. 2007, 94:99-106.
8. Bush P.W., Drake R.E., Xie H., McHugo G.J., Haslett W.R. The long-term impact of employment on mental health service use and costs for persons with severe mental illness. Psychiatr. Serv. 2009, 60:1024-1031.
9. Cannon T.D., Glahn D.C., Kim J., Van Erp T.G., Karlsgodt K., Cohen M.S., et al. Dorsolateral prefrontal cortex activity during maintenance and manipulation of information in working memory in patients with schizophrenia. Arch. Gen. Psychiatry 2005, 62:1071-1080.
10. Carpenter W.T. The deficit syndrome. Am. J. Psychiatry 1994, 151:327-329.
11. Caspi A., Reichenberg A., Weiser M., Rabinowitz J., Kaplan Z., Knobler H., et al. Cognitive performance in schizophrenia patients assessed before and following the first psychotic episode. Schizophr. Res. 2003, 65:87-94.
12. Christensen A., CHristrup L.L., Fabricius P.E., Chrostowska M., Wronka M., Narkiewicz K., et al. The impact of electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial. J. Hypertens. 2010, 28:194-200.
13. Conley R.R., Kelly D.L., Love R.C., McMahon R.P. Rehospitalization risk with second-generation and depot antipsychotics. Ann. Clin. Psychiatry 2003, 15:23-31.
14. Cook J.A., Leff H.S., Blyler C.R., Gold P.B., Goldberg R.W., Mueser K.T., et al. Results of a multisite randomized trial of supported employment interventions for individuals with severe mental illness. Arch. Gen. Psychiatry 2005, 62:505-512.
15. De Hert M., van Winkel R., Wampers M., Kane J., van Os J., Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr. Res. 2007, 92:68-73.
16. Dickinson D., Harvey P. Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem. Schizophr. Bull. 2009, 35:403-414.
17. Dickinson D., Iannone V.N., Wilk C.M., Gold J.M. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry 2004, 55:826-833.
18. Dickinson D., Ramsey M.E., Gold J.M. Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia. Arch. Gen. Psychiatry 2007, 64:532-542.
19. Druss B.G., Bradford W.D., Rosenheck R.A., Radford M.J., Krumholz H.M. Quality of medical care and excess mortality in older patients with mental disorders. Arch. Gen. Psychiatry 2001, 58:565-572.
20. Evans J.D., Bond G.D., Meyer P.D., Kim H.W., Lysaker P.H., Gibson P.J., et al. Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr. Res. 2004, 70:331-342.
21. Fenton W.S., McGlashan T.H. Natural history of schizophrenia subtypes, II: positive and negative symptoms and long-term course. Arch. Gen. Psychiatry 1991, 48:978-986.
22. Fisher W.H., Barreira P.J., Geller J.L., White A.W., Lincoln A.K., Sudders M. Long stay patients in state psychiatric hospitals at the end of the 20th century. Psychiatr. Serv. 2001, 52:1051-1056.
23. Gold J.M., Goldberg R.W., McNary S.W., Dixon L.B., Lehman A.F. Cognitive correlates of job tenure among patients with severe mental illness. Am. J. Psychiatry 2002, 159:1395-1402.
24. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153:321-330.
25. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?. Schizophr. Bull. 2000, 26:119-136.
26. Harvey P.D., Bellack A.S. Toward a terminology of functional recovery in schizophrenia: is functional remission a viable concept?. Schizophr. Bull. 2009, 35:300-306.
27. Harvey P.D., Keefe R.S.E. Interpreting studies of cognitive change in schizophrenia with novel antipsychotic treatment. Am. J. Psychiatry 2001, 158:176-184.
28. Harvey P.D., McClure M.M. Data accessed from VA Central office records, February 2008 2008.
29. Harvey P.D., Jacobsen H., Mancini D., Parrella M., White L., Haroutunian V., et al. Clinical, cognitive and functional characteristics of long-stay patients with schizophrenia: a comparison of VA and state hospital patients. Schizophr. Res. 2000, 43:3-9.
30. Harvey P.D., Moriarty P.J., Friedman J.I., White L., Parrella M., Mohs R.C., et al. Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading scores compared to other skill areas. Biol. Psychiatry 2000, 47:962-968.
31. Harvey P.D., Helldin L., Bowie C.R., Heaton R.K., Olsson A.K., Hjarthag F., et al. Performance-based measurement of functional disability in schizophrenia: a cross-national study in the United States and Sweden. Am. J. Psychiatry 2009, 166:821-827.
32. Heaton R.K., Gladsjo J.A., Palmer B.W., Kuck J., Marcotte T.D., Jeste D.V. Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 2001, 58:24-32.
33. Hegarty J.D., Baldessarini R.J., Tohen M., Waternaux C., Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am. J. Psychiatry 1994, 151:1409-1416.
34. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-444.
35. Ho B.C., Andreasen N., Flaum M. Dependence on pubic financial support early in the course of schizophrenia. Psychiatr. Serv. 1997, 48:948-950.
36. Ho B.C., Nopoulos P., Flaum M., Arndt S., Andreasen N.C. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am. J. Psychiatry 1998, 155:1196-1201.
37. Jeste S.D., Patterson T.L., Palmer B.W., Dolder C.R., Goldman S., Jeste D.V. Cognitive predictors of medication adherence among middle-aged and older outpatients with schizophrenia. Schizophr. Res. 2003, 63:49-58.
38. Kane J., Honigfeld G., Singer J., Meltzer H.Y. Clozapine for the treatment resistant schizophrenia: a double blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
39. Karagianis J., Novick D., Penecak J., Haro J.M., Dossenbach M., Treuer T., et al. Worldwide-Schizophrenia Outpatient Health Outcomes(W-SOHO): baseline characteristics of pan-regional observational data from more than 17,000 patients. Int. J. Clin. Pract. 2009, 63(11):1578-1588.
40. Keefe R.S.E., Bilder R.M., Harvey P.D., Davis S.M., Palmer B.W., Gold J.M., et al. Baseline neurocognitive deficits in the CATIE schizophrenia trial. Neuropsychopharmacology 2006, 31:2033-2046.
41. Kirkpatrick B., Buchanan R.W., Ross D.E., Carpenter W.T. A separate disease within the syndrome of schizophrenia. Arch. Gen. Psychiatry 2001, 58:165-171.
42. Kraepelin E. Dementia Praecox and Paraphrenia 1919, E.S. Livingstone, Edinburgh.
43. Kremen W.S., Seidman L.J., Faraone S.V., Toomey R., Tsuang M.T. The paradox of normal neuropsychological function in schizophrenia. J. Abnorm. Psychol. 2000, 109:743-752.
44. Leifker F.R., Bowie C.R., Harvey P.D. The determinants of everyday outcomes in schizophrenia: influences of cognitive impairment, clinical symptoms, and functional capacity. Schizophr. Res. 2009, 115:82-87.
45. Leung W.W., Bowie C.R., Harvey P.D. Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: a cross-sectional study. J. Int. Neuropsychol. Soc. 2008, 14:479-488.
46. Lieberman J.A., ALvir J.M., Koreen A., Geisler S., Chakos M., Sheitman B., et al. Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology 1996, 14:13S-21S.
47. Mahmoud R.A., Engelhart L.M., Janagap C.C., Oster G., Ollendorf D. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin. Drug Investig. 2004, 24:275-286.
48. Mausbach B.T., Harvey P.D., Goldman S.R., Jeste D.V., Patterson T.L. Development of a brief scale of everyday functioning in persons with serious mental illness. Schizophr. Bull. 2007, 33:1364-1372.
49. Mausbach B.T., Harvey P.D., Pulver A.E., Depp C.A., Wolyniec P.S., Thornquist M.H., et al. Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. Bipolar Disord. 2010, 12:45-55.
50. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80:19-32.
51. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23:315-336.
52. Mohamed S., Rosenheck R., Swartz M., Stroup S., Lieberman J.A., Keefe R.S. Relationship of cognition and psychopathology to functional impairment in schizophrenia. Am. J. Psychiatry 2008, 165:978-987.
53. Mojtabai R., Bromet E.J., Harvey P.D., Carlson G.A., Craig T.J., Fennig S. Neuropsychological differences between first admission schizophrenia and psychotic affective disorders. Am. J. Psychiatry 2000, 157:1453-1460.
54. Nasrallah H.A., Meyer J.M., Goff D.C., McEvoy J.P., Davis S.M., Stroup T.S., et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr. Res. 2006, 86:15-22.
55. Palmer B.W., Heaton R.K., Paulsen J.S., Kuck J., Braff D., Harris M.J., et al. Is it possible to be schizophrenic and neuropsychologically normal?. Neuropsychology 1997, 11:437-447.
56. Palmer B.W., Heaton R.K., Gladsjo J.A., Evans J.D., Patterson T.L., Golshan S., et al. Heterogeneity in functional status among older outpatients with schizophrenia: employment history, living situation, and driving. Schizophr. Res. 2002, 55:205-215.
57. Patterson T.L., Semple S.J., Shaw W.S., Halpain M., Moscona S., Grant I., et al. Self-reported social functioning among older patients with schizophrenia. Schizophr. Res. 1997, 27:199-210.
58. Patterson T.L., Moscona S., McKibbin C.L., Davidson K., Jeste D.V. Social skills performance assessment among older patients with schizophrenia. Schizophr. Res. 2001, 48:351-360.
59. Patterson T.L., Mausbach B.T., McKibbin C., Goldman S., Bucardo J., Jeste D.V. Functional adaptation skills training (FAST): a randomized trial of psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophr. Res. 2006, 86:291-299.
60. Reichenberg A., Harvey P.D., Bowie C.R., Mojtabai R., Rabinowitz J., Heaton R.K., et al. Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders. Schizophr. Bull. 2009, 35:1022-1029.
61. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry 1999, 56:241-247.
62. Robinson D.G., Woerner M.G., McMeniman M., Mendelowitz A., Bilder R.M. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 2004, 161:473-479.
63. Rosenheck R., Leslie D., Keefe R., McEvoy J., Swartz M., Perkins D., et al. Barriers to employment for people with schizophrenia. Am. J. Psychiatry 2006, 163:411-417.
64. Saykin A.J., Gur R.C., Gur R.E., Mozeley D., Mozeley L.H., Resnick S.M. Neuropsychological function in schizophrenia: selective impairment in memory and learning. Arch. Gen. Psychiatry 1991, 48:618-623.
65. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniack P., et al. Neuropsychological deficits in neuroleptic naive patients with first episode schizophrenia. Arch. Gen. Psychiatry 1994, 51:124-131.
66. Tamminga C.A., Thaker G.K., Buchanan R., Kirkpatrick B., Alphs, et al. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. Arch. Gen. Psychiatry 1992, 49:522-530.
67. Tamminga C.A., Buchanan R.W., Gold J.M. The role of negative symptoms and cognitive dysfunction in schizophrenia outcome. Int. Clin. Psychopharmacol. 1998, 13(Suppl. 3):S21-S26.
68. Velligan D.I., Weiden P.J., Sajatovic M., Scott J., Carpenter D., Ross R., et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J. Clin. Psychiatry 2009, 70:1-46.
69. Weiden P.J., Kozma C., Grogg A., Locklear J. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr. Serv. 2004, 55:886-891.
70. Wilk C.M., Gold J.M., McMahon R.P., Humber K., Iannone V.N., Buchanan R.W. No, it is not possible to be schizophrenic yet neuropsychologically normal. Neuropsychology 2005, 19:778-786.
71. Woodberry K.A., Giuliano A.J., Seidman L.J. Premorbid IQ in schizophrenia: a meta-analytic review. Am. J. Psychiatry 2008, 165:579-587.
72. Wykes T., Stuart E. The measurement of social behavior in psychiatric patients and assessment of the reliability and validity of the SBS schedule. Br. J. Psychiatry 1986, 148:1-11.